The allosteric site for the nascent cell wall in penicillin-binding protein 2a: An achilles' heel of methicillin-resistant staphylococcus aureus

Current Medicinal Chemistry

Volumn 22, Issue 14, 2015, Pages 1678-1686

  Acebrón, Iván ^a   Chang, Mayland ^b   Mobashery, Shahriar ^b   Hermoso, Juan A ^a  

^a INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Allosteric mechanism; Antibiotic resistance; Conformational change; Methicillin resistant Staphylococcus aureus; Penicillin binding proteins; X ray crystallography; lactam antibiotics

Indexed keywords

BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; PENICILLIN BINDING PROTEIN 2A; ANTIINFECTIVE AGENT; BETA LACTAM; PENICILLIN BINDING PROTEIN; PENICILLIN-BINDING PROTEIN 2A, STREPTOCOCCUS; PEPTIDE SYNTHASE;

ALLOSTERISM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; ENZYME ACTIVE SITE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PROTEIN CONFORMATION; STAPHYLOCOCCUS AUREUS; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL WALL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST;

ALLOSTERIC SITE; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CELL WALL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; PEPTIDE SYNTHASES;

EID: 84931275458     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150311150215     Document Type: Article

References (46)

1. Fears, R.; ter Meulen, V. What do we need to do to tackle antimicrobial resistance? The Lancet. Global Health, 2014, 2(1), e11-12.
2. WHO Antimicrobial Resistance. Global Report on Surveillance; World Health Organization: 2014.
3. CDC Antibiotic Resistance Threats in the United States; Centers for Disease Control and Prevention 2013.
4. van der Meer, J. W.; Fears, R.; Davies, S. C.; ter Meulen, V. Antimicrobial innovation: combining commitment, creativity and coherence. Nat. Rev. Drug Discov., 2014, 13(10), 709-710.
5. Kreiswirth, B.; Kornblum, J.; Arbeit, R. D.; Eisner, W.; Maslow, J. N.; McGeer, A.; Low, D. E.; Novick, R. P. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science, 1993, 259(5092), 227-230.
6. Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridkin, S. K.; Active Bacterial Core surveillance, M. I. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA, 2007, 298(15), 1763-1771.
7. Jevons, M. P.; Rolinson, G. N.; Knox, R. Celbenin-Resistant Staphylococci. Br. Med. J., 1961, 1(521), 124-125.
8. Walsh, C. Deconstructing vancomycin. Science, 1999, 284, (5413), 442-443.
9. French, G. L. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J. Antimicrob. Chemother., 2006, 58(6), 1107-1117.
10. Hernandez, P. O.; Lema, S.; Tyring, S. K.; Mendoza, N. Ceftaroline in complicated skin and skin-structure infections. Infect. Drug Resist., 2012, 5, 23-35.
11. Wilcox, M. H. Update on linezolid: The first oxazolidinone antibiotic. Expert Opin. Pharmacother., 2005, 6(13), 2315-2326.
12. Stryjewski, M. E.; Corey, G. R. Methicillin-resistant Staphylococcus aureus: An evolving pathogen. Clin. Infect. Dis., 2014, 58( Suppl 1), S10-19.
13. Johnson, J. W.; Fisher, J. F.; Mobashery, S. Bacterial cell-wall recycling. Ann. N. Y. Acad. Sci., 2013, 1277, 54-75.
14. Goffin, C.; Ghuysen, J. M. Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol. Mol. Biol. Rev., 2002, 66(4), 702-738.
15. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J. A.; Charlier, P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev., 2008, 32(2), 234-258.
16. Macheboeuf, P.; Contreras-Martel, C.; Job, V.; Dideberg, O.; Dessen, A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol. Rev., 2006, 30(5), 673-691.
17. Tipper, D. J.; Strominger, J. L. Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-D-alanyl-Dalanine. Proc. Natl. Acad. Sci. USA, 1965, 54(4), 1133-1141.
18. Ghuysen, J. M.; Frere, J. M.; Leyh-Bouille, M.; Nguyen-Disteche, M.; Coyette, J. Active-site-serine D-alanyl-D-alanine-cleavingpeptidase-catalysed acyl-transfer reactions. Procedures for studying the penicillin-binding proteins of bacterial plasma membranes. Biochem. J., 1986, 235(1), 159-165.
19. Zapun, A.; Contreras-Martel, C.; Vernet, T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol. Rev., 2008, 32(2), 361-385.
20. Pinho, M. G.; Filipe, S. R.; de Lencastre, H.; Tomasz, A. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J. Bacteriol., 2001, 183(22), 6525-6531.
21. Fuda, C.; Hesek, D.; Lee, M.; Morio, K.; Nowak, T.; Mobashery, S. Activation for catalysis of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus by bacterial cell wall. J. Am. Chem. Soc., 2005, 127(7), 2056-2057.
22. Villegas-Estrada, A.; Lee, M.; Hesek, D.; Vakulenko, S. B.; Mobashery, S. Co-opting the cell wall in fighting methicillinresistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc., 2008, 130(29), 9212-9213.
23. Lim, D.; Strynadka, N. C. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol., 2002, 9(11), 870-876.
24. Wu, C. Y.; Alborn, W. E. Jr.; Flokowitsch, J. E.; Hoskins, J.; Unal, S.; Blaszczak, L. C.; Preston, D. A.; Skatrud, P. L. Site-directedmutagenesis of the mecA gene from a methicillin-resistant strain of Staphylococcus aureus. J. Bacteriol., 1994, 176(2), 443-449.
25. Otero, L. H.; Rojas-Altuve, A.; Llarrull, L. I.; Carrasco-Lopez, C.; Kumarasiri, M.; Lastochkin, E.; Fishovitz, J.; Dawley, M.; Hesek, D.; Lee, M.; Johnson, J. W.; Fisher, J. F.; Chang, M.; Mobashery, S.; Hermoso, J. A. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc. Natl. Acad. Sci. USA, 2013, 110(42), 16808-16813.
26. Lovering, A. L.; Gretes, M. C.; Safadi, S. S.; Danel, F.; de Castro, L.; Page, M. G.; Strynadka, N. C. Structural insights into the antimethicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole. J. Biol. Chem., 2012, 287(38), 32096-32102.
27. Duplessis, C.; Crum-Cianflone, N. F. Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). Clin. Med. Rev. Ther., 2011, 3.
28. Goodey, N. M.; Benkovic, S. J. Allosteric regulation and catalysis emerge via a common route. Nat. Chem. Biol., 2008, 4(8), 474-482.
29. Navratna, V.; Nadig, S.; Sood, V.; Prasad, K.; Arakere, G.; Gopal, B. Molecular basis for the role of Staphylococcus aureus penicillin binding protein 4 in antimicrobial resistance. J. Bacteriol., 2010, 192(1), 134-144.
30. Lovering, A. L.; de Castro, L. H.; Lim, D.; Strynadka, N. C. Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science, 2007, 315(5817), 1402-1405.
31. Yoshida, H.; Kawai, F.; Obayashi, E.; Akashi, S.; Roper, D. I.; Tame, J. R.; Park, S. Y. Crystal structures of penicillin-binding protein 3 (PBP3) from methicillin-resistant Staphylococcus aureus in the apo and cefotaxime-bound forms. J. Mol. Biol., 2012, 423(3), 351-364.
32. Gordon, E.; Mouz, N.; Duee, E.; Dideberg, O. The crystal structure of the penicillin-binding protein 2x from Streptococcus pneumoniae and its acyl-enzyme form: implication in drug resistance. J. Mol. Biol., 2000, 299(2), 477-485.
33. Pinho, M. G.; de Lencastre, H.; Tomasz, A. Cloning, characterization, and inactivation of the gene pbpC, encoding penicillin-binding protein 3 of Staphylococcus aureus. J. Bacteriol., 2000, 182(4), 1074-1079.
34. Long, S. W.; Olsen, R. J.; Mehta, S. C.; Palzkill, T. G.; Cernoch, P. L.; Perez, K. K.; Musick, W. L.; Rosato, A. E.; Musser, J. M. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother., 2014, 58, 6668-6674.
35. Fishovitz, J.; Rojas-Altuve, A.; Otero, L. H.; Dawley, M.; Carrasco-Lopez, C.; Chang, M.; Hermoso, J. A.; Mobashery, S. Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. J. Am. Chem. Soc., 2014, 136(28), 9814-9817.
36. Lowy, F. D. Antimicrobial resistance: The example of Staphylococcus aureus. J. Clin. Invest., 2003, 111(9), 1265-1273.
37. Fisher, J. F.; Meroueh, S. O.; Mobashery, S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev., 2005, 105(2), 395-424.
38. Fuda, C. C.; Fisher, J. F.; Mobashery, S. Beta-lactam resistance in Staphylococcus aureus: The adaptive resistance of a plastic genome. Cell. Mol. Life Sci.: CMLS, 2005, 62(22), 2617-2633.
39. Fisher, J. F.; Mobashery, S. In Comprehensive Natural Products Chemistry II: Chemistry and Biology. Mander, L.; Liu, H. W. Eds.; Elsevier: Oxford, 2010, pp. 443-487.
40. Perutz, M. F.; Bolton, W.; Diamond, R.; Muirhead, H.; Watson, H. C. Structure of Haemoglobin. An X-Ray examination of reduced horse haemoglobin. Nature, 1964, 203, 687-690.
41. Sprang, S. R.; Acharya, K. R.; Goldsmith, E. J.; Stuart, D. I.; Varvill, K.; Fletterick, R. J.; Madsen, N. B.; Johnson, L. N. Structural changes in glycogen phosphorylase induced by phosphorylation. Nature, 1988, 336(6196), 215-221.
42. Changeux, J. P. Allosteric receptors: from electric organ to cognition. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 1-38.
43. Changeux, J. P. Allostery and the Monod-Wyman-Changeux model after 50 years. Annu. Rev. Biophys., 2012, 41, 103-133.
44. Mitra, A.; Sept, D. Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules. Biophys. J., 2008, 95(7), 3252-3258.
45. Palomo, V.; Soteras, I.; Perez, D. I.; Perez, C.; Gil, C.; Campillo, N. E.; Martinez, A. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J. Med. Chem,. 2011, 54(24), 8461-8470.
46. Fenton, A. W. Identification of allosteric-activating drug leads for human liver pyruvate kinase. Methods Mol. Biol., 2012, 796, 369-382